Fr. 70.00

Cancer Screening in Inflammatory Bowel Disease - A Guide to Risk Management and Techniques

Inglese · Copertina rigida

Spedizione di solito entro 6 a 7 settimane

Descrizione

Ulteriori informazioni

This book provides a concise, yet comprehensive overview of cancer risks in patients with inflammatory bowel disease (IBD), as well as the screening modalities used to reduce these risks. Each chapter presents a major malignancy that patients with IBD are at risk from, stemming from the disease itself or from the medications used to treat the disease. Malignancies covered include colorectal cancer, skin cancer, lymphoma, and other cancers. Cancer risk and screening with current and emerging drug therapies are also discussed.
Written by experts in the field, Cancer Screening in Inflammatory Bowel Disease: A Guide to Risk Management and Techniques is a valuable resource for gastroenterologists, colorectal surgeons, and primary care physicians who treat and manage patients with inflammatory bowel disease.

Sommario

Epidemiology and Risk Factors for Colorectal Cancer in Inflammatory Bowel Diseases.- Screening for Colon Cancer in Inflammatory Bowel Disease.- Skin Cancer Risk and Screening in Patients with Inflammatory Bowel Disease.- Female Specific Cancern Risks and Screening in Inflammatory Bowel Disease.- Lymphoma Risk and Screening in Inflammatory Bowel Disease.- Pouch Neoplasia following IPAA in Patients with Underlying Inflammatory Bowel Diseases.- Other Cancers: Small Bowel Cancers, Cholangiocarcinoma, Urinary Tract, and Anal Cancer Risk and Screening in Inflammatory Bowel Disease.- Cancer Risks and Screening with Current and Emerging Drug Therapies in Inflammatory Bowel Diseases.- Preventing Colorectal Cancer in Patients with Inflammatory Bowel Diseases: Chemopreventive and Surgical Approaches.- Cancer Risk and Screening in Pediatric Patients.- Colorectal Cancer Risk and Screening in Geriatric Patients.- Use of Biologic Drugs Following an Initial Diagnosis of Malignancy.

Info autore

Joseph D. Feuerstein, MDBeth Israel Deaconess Medical CenterCenter for Inflammatory Bowel DiseaseHarvard Medical SchoolBoston, MAUSA
Adam S. Cheifetz, MDBeth Israel Deaconess Medical CenterCenter for Inflammatory Bowel DiseaseHarvard Medical SchoolBoston, MAUSA

Riassunto

This book provides a concise, yet comprehensive overview of cancer risks in patients with inflammatory bowel disease (IBD), as well as the screening modalities used to reduce these risks. Each chapter presents a major malignancy that patients with IBD are at risk from, stemming from the disease itself or from the medications used to treat the disease. Malignancies covered include colorectal cancer, skin cancer, lymphoma, and other cancers. Cancer risk and screening with current and emerging drug therapies are also discussed. 
Written by experts in the field, Cancer Screening in Inflammatory Bowel Disease: A Guide to Risk Management and Techniques is a valuable resource for gastroenterologists, colorectal surgeons, and primary care physicians who treat and manage patients with inflammatory bowel disease.

Dettagli sul prodotto

Con la collaborazione di Adam S. Cheifetz (Editore), Josep D Feuerstein (Editore), Joseph D Feuerstein (Editore), Joseph D. Feuerstein (Editore), S Cheifetz (Editore), S Cheifetz (Editore)
Editore Springer, Berlin
 
Lingue Inglese
Formato Copertina rigida
Pubblicazione 31.08.2019
 
EAN 9783030153007
ISBN 978-3-0-3015300-7
Pagine 174
Dimensioni 160 mm x 238 mm x 14 mm
Peso 431 g
Illustrazioni XI, 174 p. 14 illus. in color.
Categorie Scienze naturali, medicina, informatica, tecnica > Medicina > Branche cliniche

B, Medicine, Surgery, INTERNAL MEDICINE, Oncology, Gastroenterology, colorectal surgery, Rectum—Surgery, Gastrointestinal & colorectal surgery

Recensioni dei clienti

Per questo articolo non c'è ancora nessuna recensione. Scrivi la prima recensione e aiuta gli altri utenti a scegliere.

Scrivi una recensione

Top o flop? Scrivi la tua recensione.

Per i messaggi a CeDe.ch si prega di utilizzare il modulo di contatto.

I campi contrassegnati da * sono obbligatori.

Inviando questo modulo si accetta la nostra dichiarazione protezione dati.